Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Akebia Therapeutics, a biopharmaceutical company focused on improving the lives of people with kidney disease, announced that its CEO, John Butler, will participate in the H.C.

Rhea-AI Summary

Akebia Therapeutics, a biopharmaceutical company focused on improving the lives of people with kidney disease, announced that its CEO, John Butler, will participate in the H.C. Wainwright 3rd Annual Kidney Virtual Conference.

The event is set for Monday, July 15, 2024, at 9:30 a.m. ET. During the conference, Butler will provide updates on the commercial launch activities for Vafseo (vadadustat) Tablets.

Interested parties can access a webcast of the presentation through the Investors section of Akebia's website for 30 days following the event. This conference is an important platform for Akebia to showcase its advancements and strategies in the kidney disease sector.

Argus Session date unavailable

+6.98% session move Open Argus

Details

News Market Reaction – AKBA

The recorded move for AKBA in the trading session of this news was +6.98%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., June 27, 2024 /PRNewswire/ -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in the H.C. Wainwright 3^rd Annual Kidney Virtual Conference on Monday, July 15, 2024. Mr. Butler will present at 9:30 a.m. ET to provide updates on the progress of commercial launch activities for Vafseo® (vadadustat) Tablets.

A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-hc-wainwright-3rd-annual-kidney-virtual-conference-302184495.html

SOURCE Akebia Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date of Akebia Therapeutics' presentation at the H.C. Wainwright 3rd Annual Kidney Virtual Conference?

Akebia Therapeutics will present on Monday, July 15, 2024.

Who will represent Akebia Therapeutics at the H.C. Wainwright 3rd Annual Kidney Virtual Conference?

John Butler, CEO of Akebia Therapeutics, will represent the company.

What will Akebia Therapeutics present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference?

Akebia Therapeutics will provide updates on the commercial launch activities for Vafseo (vadadustat) Tablets.

How can I access the webcast of Akebia Therapeutics' presentation at the H.C. Wainwright 3rd Annual Kidney Virtual Conference?

The webcast can be accessed through the Investors section of Akebia's website for 30 days following the conference.

What is the stock symbol for Akebia Therapeutics?

The stock symbol for Akebia Therapeutics is AKBA.